Baskin will oversee a large, multidisciplinary cancer center comprising 250 scientists and clinical investigators. She will be the fifth director since Massey received its National Cancer Institute (NCI) designation in 1975—an inflection point that underscores how the center’s priorities are evolving alongside national expectations for translational impact and equity-focused outreach.

Her career has centered on a community-to-bench model of cancer care. Rather than treating engagement as an afterthought, Baskin’s approach integrates behavioral, social, and environmental determinants into the design of prevention, screening, treatment, and survivorship strategies. This framework supports technical pathways that connect real-world constraints—access, trust, and context—with measurable clinical and behavioral outcomes.

A major emphasis in her work involves lifestyle interventions aimed at improving cancer-related behaviors and health outcomes, including diet, physical activity, and obesity risk. Such outcomes are particularly relevant for rural populations and communities that have historically faced barriers to cancer prevention and care. By targeting modifiable behaviors, her research translates population-level risk factors into intervention-ready programs.

VCU President Michael Rao, Ph.D., highlighted Baskin’s publication record and community-centered research as central to her readiness for the role. He also noted her recent performance as Massey’s deputy director, describing her as a driver of cutting-edge research with direct impact for the center’s catchment area.

Since joining Massey in February 2025, Baskin has strengthened the center’s influence across central, southern, and eastern Virginia. She has also elevated Massey’s national profile through leadership in academic societies, including former presidency of the Society of Behavioral Medicine (SBM) and board service roles connected to academic medical centers and community outreach and education.

Baskin’s motivation is personal as well as scientific. Raised in Atlanta, she lost her father to colorectal cancer during her senior year of high school, and later experienced additional family losses to cancer. Those events guided her training in psychology and her focus on cancer prevention, early detection, and mental health.

With more than $70 million in National Institutes of Health (NIH) grant involvement as a principal investigator or team leader, Baskin has also contributed to Cancer Center Support Grant (CCSG) review panels. That experience positions her to lead Massey through renewal of its CCSG and comprehensive-designated status, which the center earned for the first time in 2023.

Beyond directing Massey, she serves as associate dean for cancer innovation in the VCU School of Medicine and holds professor appointments spanning internal medicine and social and behavioral sciences. Her appointment is expected to reinforce a data-driven, equity-forward translation engine—one that aims to reduce cancer burden through both science and community partnership.

Subject of Research: Community-to-bench cancer prevention and lifestyle interventions (behavioral, social, and environmental determinants)
Article Title: Monica L. Baskin to Become Next Director of VCU Massey Comprehensive Cancer Center
News Publication Date:
Web References:
References:
Image Credits: VCU Massey Comprehensive Cancer Center
Keywords: VCU Massey, Monica L. Baskin, cancer center director, community-to-bench model, NCI-designated, cancer prevention, screening, lifestyle interventions, health equity, rural health

The Dr. Eddie Méndez Scholar Award, named to honor the legacy of Dr. Eddie Méndez—a pioneering clinician and researcher renowned for exemplary contributions to head and neck oncology—serves as a beacon of encouragement and support for emerging researchers. Its purpose is to accelerate innovative investigations that address complex biological challenges within oncology and infectious diseases, focusing on areas such as tumor microenvironment dynamics, T-cell differentiation pathways, and metastatic dissemination processes.

This year’s cohort includes investigators affiliated with leading academic institutions including Stanford Medicine, Harvard-affiliated research bodies, UCSF, and the Howard Hughes Medical Institute. Their collective expertise spans a range of cutting-edge disciplines, from cellular immunology to molecular biology, underscoring the multidisciplinary approach necessary for contemporary biomedical breakthroughs. The recipients’ research delves deeply into the cellular ecosystems of tumors, deciphering how stromal interactions influence immune evasion and metastatic potential, and examining the genetic and epigenetic regulation of immune effector cells.

Among the awarded scientists, Dr. Rachael Chanin from Stanford Medicine investigates the complexities of tumor ecology, particularly emphasizing how cancer cells manipulate their surrounding microenvironment to facilitate evasion of immune surveillance. Her work employs high-dimensional single-cell sequencing and spatial transcriptomics, technologies that enable resolution of tumor architecture at unprecedented granularity. This approach is critical for identifying novel biomarkers and therapeutic targets that disrupt protumorigenic niches.

Similarly, Dr. Mohamed El-Brolosy of the Whitehead Institute applies cutting-edge CRISPR-based functional genomics to dissect the regulatory networks controlling T-cell differentiation. His focus on T-cell lineage commitment offers profound implications for immunotherapy design, particularly in enhancing the efficacy of adoptive cell transfer and checkpoint blockade therapies. By elucidating molecular switch points, this research aims to overcome resistance mechanisms that limit current immunotherapies.

Dr. Amy C. Fan at UCSF explores the molecular pathways driving cancer metastasis, a process responsible for the majority of cancer-related deaths. Utilizing sophisticated in vivo imaging and genetic lineage tracing, her studies elucidate how metastatic cells acquire invasive phenotypes and adapt to distant microenvironments. These insights are poised to inform innovative intervention strategies capable of arresting metastatic dissemination at its earliest stages.

The cohort also includes Dr. Mario Palma from the Harvard T.H. Chan School of Public Health, whose investigations into immune modulation focus on cytokine signaling and its impact on tumor progression. His work integrates systems biology modeling with experimental immunology to uncover how inflammatory circuits within tumors influence disease trajectory and patient response to therapy.

Reflecting on the significance of the award, Dr. Christina Termini, assistant professor and co-director of the program, emphasized the rigorous selection process and the exceptional caliber of candidates. She highlighted the transformative potential embodied by these emerging leaders as they apply novel methodologies to unravel complex biological questions that underpin effective cancer treatment paradigms.

Dr. Christopher Li, who co-directs the awards alongside Termini, noted that the award’s namesake embodied a holistic approach to cancer care, one that prioritized patient welfare alongside scientific innovation. The recipients resonate with this philosophy by striving not only for mechanistic insights but also translational impact, ensuring that their discoveries will improve treatment outcomes and patient quality of life.

Since its inception in memory of Dr. Méndez, the award has recognized over seventy postdoctoral researchers, creating a vibrant network of scholars who collectively advance cancer biology and therapeutics. This year’s symposium, scheduled for mid-July at the Fred Hutch Campus in Seattle, provides a vital forum for dialogue, collaboration, and dissemination of these pioneering works among faculty, clinical leaders, and peers.

Fred Hutchinson Cancer Center continues to cement its reputation as a powerhouse of innovation, leveraging cross-disciplinary expertise and state-of-the-art technologies to confront some of the most challenging issues in oncology and infectious disease research. Through initiatives like the Dr. Eddie Méndez Scholar Award, it nurtures the next wave of visionary scientists dedicated to transforming cancer care and ultimately achieving curative therapies.

The accomplishments and ambitions of these eight distinguished awardees underline the evolving landscape of cancer research, where integrated approaches spanning molecular biology, immunology, and clinical translation are essential. Their work not only expands the fundamental understanding of cancer pathophysiology but also promises to define new paradigms for precision medicine, immunotherapy, and patient-centered care.

As the scientific community awaits the outcomes of these promising investigations, the Dr. Eddie Méndez Scholar Award stands as a testament to the enduring impact of mentorship, innovation, and dedication in the relentless pursuit of cancer eradication.

Subject of Research: Cancer biology, tumor microenvironment, T-cell differentiation, cancer metastasis, immunotherapy
Article Title: Rising Stars in Cancer Research: The 2026 Dr. Eddie Méndez Scholar Award Recipients
News Publication Date: June 23, 2026
Web References:
– Fred Hutch Cancer Center faculty directory and award program information
References: Not explicitly provided within the article content
Image Credits: Fred Hutch Cancer Center
Keywords: Dr. Eddie Méndez Scholar Award, cancer research, tumor microenvironment, T-cell differentiation, metastasis, immunotherapy, early-career scientists, Fred Hutchinson Cancer Center

The multidisciplinary team, drawing expertise from both the Faculty of Medical Sciences (FCM) and the Gleb Wataghin Institute of Physics (IFGW) at UNICAMP, embarked on this research with backing from multiple grants awarded by the São Paulo Research Foundation (FAPESP). Their efforts culminated in the development of what they have termed the Visceral Muscle Difference (VMD) marker—a composite variable that captures metabolic and inflammatory properties of patient body composition using quantitative imaging parameters.

Conventionally, gastric cancer prognosis centers around tumor staging, an approach focusing primarily on the characteristics and spread of the tumor itself. However, this research introduces a paradigm shift by emphasizing the patient’s overall physiological state—not just the malignancy. The investigative team, including Professor José Barreto and co-advisor Jun Takahashi, advocates a holistic perspective that scrutinizes how body composition influences cancer outcomes, highlighting that tailored treatment must address the patient’s systemic condition to improve survival.

Central to the study was the analysis of data collected over a decade from 461 patients treated for gastric cancer at UNICAMP. Researchers meticulously analyzed their CT scans, quantifying radiodensity values of visceral adipose tissue and skeletal muscle. Radiodensity, an indicator of tissue’s capacity to attenuate X-rays during CT scanning, holds clues to underlying biological processes such as inflammation and metabolic health—factors increasingly recognized as critical modifiers of cancer progression.

By integrating these radiodensity values into a single metric, the VMD marker captures the complex interplay between fat and muscle tissue states in cancer patients. Intriguingly, the research reveals an inverse prognostic relationship: elevated radiodensity in adipose tissue correlates with poorer outcomes, possibly signalling inflammatory activation within the fat stores, while higher muscle radiodensity aligns with better survival rates, reflecting preserved muscle quality.

Quantitative analysis demonstrated striking survival disparities based on VMD scores. Patients with elevated VMD—a signifier of detrimental body composition—experienced a median survival of just 13.8 months, starkly contrasted with 58.5 months for those exhibiting healthier VMD profiles. This prognostic ability surpasses traditional staging, offering oncologists a powerful tool to identify high-risk patients who may require intensified or alternative therapeutic approaches.

The robustness of the VMD marker is further enhanced by its design, which strategically utilizes the difference between fat and muscle radiodensity rather than relying on absolute values for each tissue. This approach mitigates variability introduced by different CT scanner calibrations or technical inconsistencies, ensuring more reliable clinical implementation across diverse healthcare settings.

Harnessing advanced artificial intelligence techniques, the team employed machine learning algorithms to sift through the extensive imaging and clinical data. Unlike traditional univariate analyses, this methodology enabled rapid testing of multiple radiodensity combinations, refining the marker until it achieved optimal prognostic precision. “Teaching the machine to align with expert clinical insight while scaling data analysis exponentially was key,” explains Takahashi.

The implications of VMD extend beyond prognostication. Integrating this biomarker into clinical workflows could revolutionize treatment decision-making by unveiling the patient’s metabolic and inflammatory status—critical determinants often overlooked in standard cancer care. Personalized treatment regimens could emerge whereby aggressive chemotherapy is selectively administered to those with high-risk VMD profiles, whereas patients with favorable metrics might avoid unnecessary toxicity post-surgery, fundamentally improving quality of life.

Despite these promising findings, researchers caution that the study’s retrospective nature necessitates validation in prospective, multicenter cohorts encompassing broader demographics. Ensuring reproducibility across different populations and clinical environments is essential before VMD can be fully incorporated into routine practice. Moreover, the potential to modify a patient’s body composition profile therapeutically remains an open question, with ongoing investigations exploring whether nutritional or metabolic interventions can positively impact prognosis.

This study situates itself firmly within the evolving landscape of precision oncology, where understanding the host’s systemic biology complements tumor biology to refine cancer management. By leveraging data from standard CT scans—already integral to patient assessment—the VMD marker offers a cost-effective, readily accessible addition to the oncologist’s toolkit without imposing extra procedural burdens on patients.

Early exploratory studies initiated by the team suggest that the predictive value of the VMD marker may extend to other cancer types, potentially heralding a universal biomarker of cancer-related frailty and inflammation. As these lines of research mature, clinicians may soon navigate cancer treatment armed with unprecedented insights into the intricate interplay between tumor and host, tailoring therapeutics with unparalleled precision.

The diligent efforts of the UNICAMP team, supported by FAPESP, exemplify how interdisciplinary collaboration, cutting-edge technology, and patient-centered philosophy can converge to solve complex medical challenges. Their work opens a new chapter in gastric cancer prognosis, where the narrative shifts from focusing solely on the tumor mass to embracing the multifaceted biological portrait of the patient as a whole—paving the way for a future where personalized medicine is truly realized.

Subject of Research: Biomarker development for prognosis in gastric cancer utilizing CT scan-derived body composition radiodensity variables

Article Title: Determination of a new gastric cancer mortality predictor based on body composition radiodensity variables

News Publication Date: March 21, 2026

Web References:

• https://www.fapesp.br/en
• https://www.agencia.fapesp.br/en
• DOI: 10.1016/j.clnesp.2026.103132

References:

• Original article published in Clinical Nutrition ESPEN, 2026

Image Credits: FCM-UNICAMP

Keywords:
Gastric cancer, biomarker, prognosis, radiodensity, visceral fat, muscle, CT scan, body composition, machine learning, personalized medicine, inflammation, metabolic state

Fibroblasts, the abundant benign cells present within the tumor stroma, have traditionally been considered passive components of the tumor microenvironment. However, this new research illustrates their dynamic role in modulating angiogenesis, the process of new blood vessel formation critical for tumor sustenance and expansion. According to Jordi Alcaraz, a professor at the University of Barcelona’s Faculty of Medicine and Health Sciences and the senior author of the study, these fibroblasts do much more than merely inhabit the tumor niche—they actively influence vascular network architecture, oxygen and nutrient availability, and potentially the metastatic potential of lung tumors along with shaping the immune landscape within the tumor milieu.

This international investigation involved multidisciplinary collaboration between prestigious institutions such as the Catalan Institute of Oncology, the Bellvitge Biomedical Research Institute, the Mayo Clinic in the United States, the Francis Crick Institute in the United Kingdom, and the Garvan Institute of Medical Research and the University of New South Wales in Australia. Spearheaded by the University of Barcelona’s researcher Natalia Díaz Valdivia, the team deployed sophisticated experimental approaches to study angiogenesis markers and hypoxia-related pathways in human lung cancer samples and animal models.

Immunotherapy, a therapy that invigorates the patient’s immune system to target cancer cells, has emerged as a promising lung cancer treatment modality. Nonetheless, many patients fail to derive benefit from immunotherapy alone. Combined therapeutic regimens integrating immunotherapy with anti-angiogenic agents have garnered attention due to their ability to normalize abnormal tumor vasculature and potentially alleviate immunosuppressive tumor niches. Despite this, squamous cell carcinoma has consistently underperformed in response to anti-angiogenic therapy, unlike adenocarcinoma where these drugs demonstrate more robust clinical success.

The researchers distinctly observed that adenocarcinomas display vigorous and functionally competent angiogenesis, characterized by elevated oxygen levels and reduced apoptotic cell death within the tumor mass. Conversely, squamous cell carcinomas were marked by poor vascularization, heightened hypoxia, and an acidic microenvironment—conditions that foster tumor survival under nutrient-deprived and oxygen-starved states but also confer resistance to anti-angiogenic treatments. This stark divergence in vascular biology was traced back to the behavior of cancer-associated fibroblasts, which interact differentially with molecular signaling pathways in these histotypes.

A key mechanistic insight uncovered relates to the synergistic interplay between vascular endothelial growth factor (VEGF) and TIMP-1 (tissue inhibitor of metalloproteinases-1), a novel pro-angiogenic factor. In lung adenocarcinoma, fibroblasts actively enhance angiogenesis through this VEGF-TIMP-1 axis alongside SMAD2/3 signaling pathways, thus facilitating the formation of a functional vascular network. On the other hand, fibroblasts in squamous cell carcinoma exhibit altered molecular profiles likely induced by chronic tobacco exposure, resulting in diminished vessel formation capability and exacerbated tumor hypoxia.

These findings not only elucidate the historically observed selective efficacy of anti-angiogenic drugs favoring adenocarcinoma patients but also shed light on the disparate metastatic behavior of these subtypes. Adenocarcinomas, with their extensive and operational blood vessel networks, seem more predisposed to early metastatic spread, leveraging the vasculature to disseminate cancer cells. Squamous tumors, burdened with hypoxia and acidic stress, appear to metastasize less readily, indicating a complex interplay between the tumor microenvironment and cancer progression dynamics.

The study drives home the imperative need for precision medicine strategies that recognize the heterogeneity of lung cancer subtypes. Therapeutic regimens must transcend one-size-fits-all paradigms, instead integrating tumor microenvironment features such as angiogenesis and hypoxia to stratify patients meaningfully. Biomarkers like TIMP-1 emerge as promising candidates for identifying patient subsets who may benefit from targeted anti-angiogenic interventions or tailored immunotherapy combinations.

Importantly, the work spotlights novel therapeutic targets relevant to these tumor microenvironment differences. For example, adenocarcinoma therapies might be optimized by focusing on agents that disrupt the pro-angiogenic TIMP-1 and SMAD3 pathways, while squamous carcinoma treatments may achieve greater efficacy by addressing tumor hypoxia and metabolic acidosis. This nuanced understanding offers a research blueprint for drug development aiming to manipulate the surrounding stroma in addition to the malignant cells themselves.

A significant practical challenge moving forward is the translation of these mechanistic discoveries into clinical practice. Researchers underscore the importance of validating biomarkers like TIMP-1 in prospective clinical trials and demonstrating that targeting stromal components alongside cancer cells genuinely enhances patient outcomes. The identification and development of specific inhibitors against TIMP-1, currently lacking, represent a critical avenue for therapeutic innovation.

The study received funding from prominent sources including the Spanish National Research Council, the European Union’s Horizon 2020 program, and the Spanish Association Against Cancer. As the global burden of lung cancer continues to rise, innovations that dissect and exploit the tumor microenvironment’s complexity may significantly impact therapeutic efficacy and survival rates for patients worldwide.

Overall, this comprehensive research not only deepens the scientific community’s understanding of lung cancer biology but also paves the way for next-generation treatment strategies that are finely tailored to histotype-specific microenvironmental characteristics, heralding a new era of personalized oncology.

Subject of Research: Cells

Article Title: Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer

News Publication Date: March 30, 2026

Web References:
https://doi.org/10.1038/s41419-026-08677-2

References:
Published in Cell Death & Disease, 2026

Image Credits: UNIVERSITY OF BARCELONA

Keywords: Lung Cancer, Adenocarcinoma, Squamous Cell Carcinoma, Anti-angiogenic Therapy, Tumor Microenvironment, Fibroblasts, Angiogenesis, TIMP-1, VEGF, Hypoxia, Immunotherapy, Personalized Therapy

A highlight of this year’s presentations includes a major symposium by Dr. Stephen J. Forman, focused on the transformative potential of first-line chimeric antigen receptor (CAR) T cell therapy in adults diagnosed with acute lymphoblastic leukemia (ALL). CAR T cell therapy has revolutionized treatment paradigms for certain blood cancers by engineering a patient’s immune cells to specifically target and destroy malignant cells. Dr. Forman’s discussion will encompass clinical trial data and mechanistic insights into how initial CAR T therapy can optimize remission rates and durability for ALL patients, a population traditionally burdened with high relapse risk.

In parallel, Dr. Robert R. Jenq will deliver crucial insights into how the gut microbiome modulates patient responses to CAR T therapy. By studying the complex microbial ecosystems within patients, his research elucidates why some individuals experience remarkable therapeutic success while others encounter resistance or severe side effects. This emerging area leverages advances in metagenomics and immunology, positioning the microbiome as a key determinant of immunotherapeutic efficacy.

A standout study employs artificial intelligence (AI) to dissect gut microbiome differences implicated in early-onset colorectal cancer (CRC), a phenomenon increasingly diagnosed in younger adults. By integrating microbiome sequencing data with tumor genomics, clinical features, and social determinants of health, investigators applied sophisticated AI models to reveal reduced microbial diversity and distinct compositional shifts associated with early disease development. These findings, spearheaded by doctoral candidate Sophia Manjarrez and senior author Dr. Enrique Velazquez-Villarreal, highlight the multifactorial etiology of CRC and underscore the importance of a systems biology approach to uncover hidden biological signatures.

Another pivotal contribution from City of Hope researchers uncovers a heretofore unrecognized molecular pathway underpinning immune resistance in microsatellite-stable (MSS) colorectal cancers, which constitute the majority of CRC cases yet remain largely refractory to immunotherapy. This pathway centers on the RNA-modifying enzyme NAT10 and its interaction with the oncogene MYC. Enhanced NAT10 activity drives autophagy-mediated degradation of MHC class I molecules, essential components for T cell recognition of tumor cells. Disrupting this axis restores immune visibility of cancer cells, potentiating responses to checkpoint blockade in preclinical models. These discoveries, presented by Dr. Junyong Weng and led by Dr. Ajay Goel, offer promising therapeutic targets to overcome a major barrier in CRC treatment.

In the domain of hematologic malignancies, City of Hope’s research reveals a critical metabolic dependency in acute myeloid leukemia (AML). The protein eIF4A1 emerges as a linchpin in leukemia cell metabolism, facilitating the synthesis and utilization of nutrients necessary for unchecked proliferation. Inhibition of eIF4A1 not only impedes cellular energy production and protein translation but also translates into significant leukemia regression and survival benefits in animal models. This metabolic vulnerability, discussed by visiting researcher Xiaoxu Zhang and principal investigator Dr. Rui Su, may herald a new avenue for AML therapy by integrating metabolic repression with conventional treatments.

Advances in AI applications continue to permeate cancer immunology, exemplified by a novel model that predicts immune system targets with greater precision. This approach integrates structural predictions of peptide-MHC complexes derived from AlphaFold 3 with geometry-aware machine learning frameworks, enhancing epitope identification even when training data is limited. By refining how immune epitopes are predicted, the model may accelerate the development of personalized cancer vaccines and immunotherapies, addressing one of immunotherapy’s fundamental challenges — identifying the peptides that effectively elicit T cell responses. The work, presented by Dr. Kamel Lahouel and senior author Dr. Cristian Tomasetti, underscores the synergy between AI and experimental immunology.

City of Hope’s presence at the AACR Annual Meeting also features late-breaking poster sessions revealing novel insights into cancer disparities and immune mechanisms. For instance, spatial transcriptomics applied to endometrial cancer in African American women uncovers distinct molecular and immune pathway alterations, which may inform tailored therapeutic strategies. Additionally, studies on variations in cancer screening rates influenced by housing status and ethnicity post-implementation of targeted healthcare strategies highlight the crucial intersection of social determinants and oncologic outcomes.

The recognition of City of Hope’s scientists with multiple awards, including Early-Career Scholar and AACR Faculty Scholar honors, attests to the institution’s commitment to fostering innovative research leadership. These accolades also reflect the broader scientific community’s acknowledgment of the transformative potential of the studies being presented.

Collectively, these presentations illustrate City of Hope’s integrated approach to cancer research, encompassing molecular biology, immunology, computational modeling, and social sciences. Emphasizing translational relevance, the institution’s work aims to bridge laboratory discoveries with clinical applications, ultimately improving patient prognosis and quality of life. By embracing advanced AI, novel therapeutic targets, and comprehensive patient profiling, City of Hope is helping to define the future landscape of precision oncology.

At the heart of these endeavors lies an overarching philosophy: cancer is a multifaceted disease requiring holistic, multidisciplinary strategies. The convergence of high-throughput data technologies, innovative computational frameworks, and molecular insights is reshaping how researchers understand tumor biology, immune evasion, and therapeutic resistance. City of Hope’s presentations at AACR 2026 are a testament to the power of this model, offering hope for new, more effective treatments for patients worldwide.

As the oncology community gathers at the AACR Annual Meeting, the City of Hope team’s contributions promise to stimulate scientific dialogue and catalyze next-generation cancer therapies. From CAR T cell innovations to microbiome-mediated immune modulation and AI-driven epitope prediction, their research exemplifies the bold strides being made to unravel cancer’s complexities and translate knowledge into cures.

Subject of Research: Cancer risk, treatment resistance, and emerging therapeutic strategies in solid and blood cancers, incorporating microbiome analysis, molecular pathways, cancer metabolism, and AI-driven immunotherapy prediction.

Article Title: City of Hope Unveils Pioneering Cancer Research at AACR Annual Meeting 2026: AI, Microbiome, Metabolism, and Immunotherapy Breakthroughs

News Publication Date: 2026

Web References:
– https://www.cityofhope.org/
– https://www.abstractsonline.com/pp8/#!/21436/
– https://www.tgen.org/

References: Not specified in detail within the original content.

Image Credits: Not provided.

Keywords: cancer research, oncology, CAR T cell therapy, acute lymphoblastic leukemia, microbiome, colorectal cancer, immunotherapy resistance, NAT10, MYC, acute myeloid leukemia, metabolism, eIF4A1, artificial intelligence, peptide-MHC prediction, cancer vaccines, AACR Annual Meeting 2026, City of Hope

Among the cutting-edge clinical trials launched this year, Alliance A212101 stands out. Co-chaired by Heather Hampel, MS, CGC, of City of Hope, and Frank Sinicrope, MD, of the Mayo Clinic, the study delves into the optimization of genetic risk sharing within families affected by colorectal cancer. It investigates whether direct communication by patients or mediated communication through healthcare providers yields greater uptake in cascade genetic testing among first-degree relatives. This paradigm shift in familial risk communication could revolutionize early detection strategies, enabling preemptive interventions through precise genetic screening.

Parallel to genetic research, Alliance A232402 CD, led by Dr. Gabriel Brooks at Dartmouth’s Geisel School of Medicine, evaluates the PAGODA algorithm designed to optimize chemotherapy delivery for gastrointestinal cancers, including colorectal tumors. This innovative Proactive Graduated Dose Modification Algorithm anticipates toxicity and adjusts chemotherapy doses preemptively, aiming to minimize unplanned treatment delays. By mitigating side effects before they fully manifest, PAGODA preserves chemotherapy efficacy and patient quality of life, presenting a proactive alternative to traditional reactive dose modifications.

Ongoing studies such as Alliance A022101, spearheaded by Eric Miller, MD, PhD, at Ohio State University, focus on advanced colorectal cancer with limited metastasis beyond the liver. This phase III trial evaluates the addition of total ablative therapy—encompassing stereotactic radiation, surgical resection, and microwave ablation—to systemic chemotherapy. The integration of local ablative modalities with systemic treatment may extend survival and redefine treatment algorithms for metastatic colorectal cancer.

In a broader gastrointestinal oncology context, the Alliance A022102 trial investigates systemic chemotherapy combinations with immunotherapy for HER2-negative advanced cancers of the esophagus, gastroesophageal junction, and stomach. Haesong Park, MD, at Dana-Farber Cancer Institute, leads this comparative study of mFOLFIRINOX versus mFOLFOX regimens with or without nivolumab. Immune checkpoint blockade in conjunction with chemotherapy may potentiate anti-tumor responses, highlighting the translational potential of combining cytotoxic and immunologic modalities in upper GI malignancies.

Addressing symptom management, the A222004 trial led by Aminah Jatoi, MD, at Mayo Clinic, is pioneering a comparative efficacy study of olanzapine versus megestrol acetate for anorexia in patients with advanced cancer, including colorectal cancer. Cancer-associated cachexia heavily contributes to morbidity and mortality, and this trial aims to identify superior appetite stimulants capable of attenuating weight loss and improving clinical outcomes.

Recognizing the role of supportive care interventions, the Alliance A222302 trial explores telehealth exercise programs for patients undergoing chemotherapy. Led by Kathryn Schmitz, PhD, MPH, and Jennifer Ligibel, MD, this innovative study tests the feasibility of remotely supervised resistance and aerobic training designed to preserve functional capacity and mitigate fatigue. Findings from this trial could fundamentally change rehabilitation strategies and enhance patient autonomy during intensive cancer therapies.

Financial toxicity remains a frequently overlooked but critical facet of cancer care. In response, the AFT A232403 PROOF trial, headed by Victoria Blinder, MD, MSc, investigates whether remote monthly screening for financial hardship, combined with navigation support, can positively influence survival and quality of life in patients with advanced cancers including colorectal neoplasms. This intersection of economic and clinical outcomes research highlights the necessity of holistic approaches to cancer management.

Preventive strategies also feature prominently in ongoing clinical efforts. The Alliance A211901 trial, known as Project Reach, utilizes text-based interventions to facilitate smoking cessation among rural cancer survivors. Since tobacco use is a significant modifiable risk factor for cancer recurrence and new primary cancers, leveraging mobile health technologies could dramatically reduce smoking prevalence and consequentially, cancer burden.

In parallel, the A212102 study spearheaded by Marie Wood, MD, is establishing a blinded reference set for multicancer early detection blood tests, incorporating cohorts with colorectal cancer and controls. These biomarker-driven efforts aim to refine liquid biopsy platforms that detect circulating tumor DNA or proteins, thereby enhancing early diagnosis when curative treatment options are feasible.

Completing the portfolio of studies is the A232301CD trial led by Angela Bradbury, MD, focusing on innovative delivery models of genetic services for adolescents and young adults (AYA) with cancer histories, including colorectal cancer survivors. This trial implements enhanced eHealth platforms and chatbot-enabled genetic counseling, addressing longstanding access disparities in community healthcare settings. By closing gaps in genetic testing and counseling, such initiatives bolster precision medicine efforts and familial risk stratification.

Collectively, these trials underscore an integrative approach to colorectal cancer that spans molecular genetics, innovative therapeutics, symptom management, lifestyle modification, and healthcare delivery optimization. The Alliance for Clinical Trials in Oncology, with over 25,000 affiliated specialists across North America, continues to push the frontier of cancer research through rigorous, practice-changing clinical studies. Their work not only promises improvements in patient outcomes but also sets new standards for comprehensive cancer care.

Engagement in these studies offers patients access to novel therapies, and for clinicians and researchers, these trials generate indispensable data to inform future practice. The Alliance’s commitment extends beyond clinical trials to include a vast biorepository with over 1.5 million samples, facilitating ongoing translational and genomic research. Through such extensive collaborations and resources, the fight against colorectal cancer is poised for significant breakthroughs in the years ahead.

The convergence of precision medicine, patient-centered communication, and supportive care represents a transformative era in oncology. As these clinical trials progress, the integration of genetic insights, digital health technologies, and proactive treatment algorithms holds the potential not only to improve survival but also to enhance the quality of life for countless individuals facing the formidable challenge of colorectal cancer.

Subject of Research: Colorectal cancer diagnostics, treatment, genetic testing, supportive care, and preventive interventions.

Article Title: Innovative Clinical Trials Illuminate New Horizons in Colorectal Cancer Care

News Publication Date: Information not provided

Web References:

• Alliance for Clinical Trials in Oncology: www.AllianceforClinicalTrialsinOncology.org
• ClinicalTrials.gov (specific studies referenced by their NCT numbers)

Image Credits: City of Hope

Keywords: Colorectal cancer, genetic testing, chemotherapy dose modification, total ablative therapy, immunotherapy, anorexia treatment, telehealth exercise, financial hardship screening, smoking cessation, multicancer detection, adolescent and young adult cancer survivors, precision medicine

Gastric cancer, a malignancy often diagnosed at advanced stages and with poor prognosis, has long puzzled researchers due to its heterogeneity and intricate interactions between cancer cells and the surrounding immune milieu. Traditional bulk tissue analyses fail to capture this spatial complexity, leading to generalized conclusions that lack the nuance needed to tailor effective, personalized treatments. By constructing a detailed three-dimensional map of gastric tumors, the researchers have created a high-resolution blueprint of cellular organization and interactions at a level never before achieved.

Central to their findings is the identification and characterization of a lymphocyte-aggregated region within the gastric cancer microenvironment. Lymphocytes, particularly T cells and B cells, play crucial roles in anti-tumor immunity, yet their distribution and functional states in gastric tumors have remained elusive. The study reveals that lymphocytes cluster in discrete regions, forming immunological niches that may represent sites of active immune surveillance or, alternately, immune evasion. These lymphocyte-rich microdomains exhibit distinct genetic and molecular profiles compared to the rest of the tumor, suggesting spatially variable immune landscapes within a single neoplasm.

Leveraging cutting-edge spatial transcriptomics and multiplexed imaging technologies, the researchers charted the precise locations of various cellular phenotypes alongside their gene expression signatures. This approach marries the power of high-throughput sequencing with spatial context, ensuring that insights into cellular function are grounded in their physical tumor niche. The atlas delineates not only the cancer cells and lymphocytes but also stromal elements, blood vessels, and myeloid cell populations, exposing a complex and heterogeneous tissue ecosystem.

Intriguingly, the lymphocyte-aggregated regions exhibited signs of immune activation and exhaustion simultaneously, suggesting a dynamic tug-of-war between tumor-promoting mechanisms and host defenses. Markers indicative of cytotoxic T cell activity were co-expressed with inhibitory receptors, hinting at a suppressed yet poised immune state. This duality may explain why some gastric cancers evade immune eradication despite significant lymphocyte infiltration, underscoring the importance of spatial context in interpreting immune signatures.

Further, the spatial atlas highlights varying metabolic and signaling pathways active within the lymphocyte aggregates, which could influence immune cell function and persistence. For example, hypoxia-inducible factors and nutrient deprivation mechanisms appear spatially enriched in certain zones, potentially modulating immune cell efficacy and shaping tumor evolution. By pinpointing these microenvironmental features, the work opens avenues to manipulate local conditions therapeutically, enhancing immunotherapy responses.

The practical implications of this study are vast. Clinicians may soon be able to leverage spatial profiling to predict patient prognosis more accurately or choose immunomodulatory treatments based on the presence and quality of lymphocyte aggregation within tumors. Moreover, pharmaceutical development can focus on designing agents that either bolster lymphocyte clusters or disrupt the immunosuppressive barriers impeding their function, refining the precision medicine paradigm.

Importantly, this research bridges a critical gap between histopathology and molecular biology. Whereas histological techniques offer insight into tissue morphology, and omics approaches reveal molecular states, this spatially resolved atlas synergizes both realms, rendering a comprehensive picture of tumor biology. As illustrated by this work, such integration is essential to unraveling the nuances of tumor-immune interplay that ultimately governs disease progression and therapeutic success.

The study also highlights how spatial heterogeneity within tumors complicates one-size-fits-all treatment strategies. The existence of micro-niches with differing immune contexts cautions against oversimplified classifications of tumors as simply “immune hot” or “cold.” Instead, this sophistication requires high-resolution approaches like spatial transcriptomics to capture the true immune landscape, which varies not only between patients but within tumors themselves.

Future research building upon this atlas can investigate temporal dynamics, examining how lymphocyte-aggregated regions develop, resolve, or remodel over time or in response to treatment. Such longitudinal spatial profiling could identify biomarkers of therapeutic response or resistance, allowing adaptive treatment modifications and thereby improving clinical outcomes for gastric cancer patients.

Moreover, these findings may hold relevance beyond gastric cancer. Many solid tumors exhibit heterogeneous immune landscapes, and the methodological framework presented here can be adapted to other malignancies. This establishes a new standard for spatially resolved cancer biology research, moving beyond snapshots of gene expression to incorporate the spatial and functional contextuality essential for clinical translation.

In conclusion, the construction of a spatially resolved atlas of gastric cancer marks a transformative moment in oncological research. By illuminating the nature of lymphocyte-aggregated regions within tumors, the study deepens our understanding of immune-tumor interaction complexities and adds an invaluable tool to the arsenal seeking to outsmart cancer. As the field advances, integrating spatial data into clinical practice promises to refine patient stratification and enhance the efficacy of immunotherapies, potentially ushering in a new era of precision oncology.

This landmark work offers not only a detailed map but a conceptual framework for how the tumor microenvironment can be dissected with exquisite resolution — a beacon guiding future discoveries in cancer immunology and therapeutic innovation. It exemplifies the power of combining state-of-the-art spatial technologies and comprehensive molecular analysis to decode the cancer ecosystem, fostering hope for improved treatments and patient survival worldwide.

Subject of Research: Gastric cancer spatial microenvironment and immune cell aggregation

Article Title: A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region

Article References: Gao, S., Qin, S., Wang, D. et al. A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68612-z

Image Credits: AI Generated

Developed by a multidisciplinary team led by Hübschmann, Kreutzfeldt, and Roth, the Knowledge Connector synthesizes diverse multiomics layers—genomics, transcriptomics, proteomics, metabolomics, and epigenomics—into a unified framework that enhances clinical interpretability without compromising scientific rigor. Unlike earlier solutions that largely focused on single-omics or simple correlations, this system harnesses cutting-edge machine learning algorithms and network-based analytics to decipher complex biological interconnections that drive tumorigenesis and therapeutic resistance. This holistic approach not only refines patient stratification but also illuminates novel molecular targets for intervention.

The architecture of the Knowledge Connector is built upon a modular design tailored for scalability and adaptability to rapidly expanding multiomics datasets. At the core, a data harmonization engine preprocesses raw data by normalizing across platforms and aligning temporal sampling points. This is followed by an integrative inference module that applies probabilistic graphical modeling to infer causal relationships between molecular events, effectively transforming static snapshots into dynamic insights of tumor biology. Crucially, this enables clinicians to explore potential treatment outcomes under different therapeutic scenarios.

From a clinical perspective, the system’s user interface is a major breakthrough. It presents multi-layered biological information through intuitive visualizations and natural language summaries, allowing oncologists to navigate from high-level patient profiles down to gene-level details. This democratization of complex data interpretation empowers informed decision-making, reducing reliance on bioinformatics specialists and accelerating the translation of molecular insights into tailored therapy plans. Early pilot studies demonstrate significantly improved concordance between recommended treatments and patient outcomes when the Knowledge Connector is employed.

One of the most impressive aspects of this platform is its integration of real-world evidence and ongoing clinical trial data via embedded knowledge graphs. By continuously updating molecular signatures with outcomes from diverse populations and emerging therapeutics, the system adapts in near real-time to evolving standards of care. This dynamic feedback loop exemplifies a shift from static, protocol-driven oncology to a data-adaptive, patient-centric model. Moreover, the system’s capacity to identify off-label drug repurposing opportunities holds promise for accelerating personalized treatment options where approved therapies fall short.

The development process itself was emblematic of modern biomedical innovation, involving close collaboration between computational scientists, molecular biologists, clinicians, and patients. Rigorous validation of the Knowledge Connector included retrospective analyses of over 2,000 multiomics profiles from diverse cancer types, as well as prospective clinical trials at multiple international centers. These efforts collectively underscore the system’s robustness and generalizability, providing a strong foundation for widespread clinical adoption.

Technical innovation also extends to the system’s machine learning framework, which incorporates explainable AI models rather than opaque “black box” approaches. This transparency is critical for clinical trust, allowing users to interrogate how predictions and recommendations are generated. Features such as attention heatmaps and ranking of influential biomarkers provide valuable interpretability, aligning with regulatory expectations and ethical considerations inherent in precision medicine.

Furthermore, the team engineered advanced data security and privacy protocols leveraging federated learning techniques. By enabling decentralized training across multiple hospital networks without centralizing sensitive patient data, the platform addresses significant barriers to data sharing while preserving compliance with stringent privacy legislations worldwide. This approach not only facilitates collaborative research but also ensures patient autonomy remains central to data governance.

In the context of multiomics-based oncology, the Knowledge Connector exemplifies the transformative potential of convergent technologies—big data analytics, systems biology, AI, and user-centered design. It represents a paradigm shift from the compartmentalized study of individual molecular aberrations toward a systemic understanding of cancer as a complex, adaptive network. This comprehensive insight is pivotal for overcoming intrinsic tumor heterogeneity and therapeutic resistance, which have historically stymied treatment success.

Looking ahead, the research team is exploring expansions of the platform to incorporate spatial omics and single-cell sequencing data, thus capturing intricate tumor microenvironment dynamics and cellular heterogeneity in even greater detail. Such enhancement promises further refinement of therapeutic predictions and personalized interventions that consider the multifaceted tumor ecosystem. In parallel, efforts are underway to scale the system’s cloud infrastructure to facilitate global access while maintaining performance and reliability.

The implications of this breakthrough extend beyond oncology. The modular, integrative strategy underpinning the Knowledge Connector serves as a blueprint for precision medicine applications across complex diseases characterized by multi-layered molecular dysregulation. By furnishing clinicians with actionable, biologically grounded insights, the platform catalyzes a future where diagnosis and treatment are not only personalized but continuously evolving alongside advances in molecular research and clinical practice.

In summary, Hübschmann, Kreutzfeldt, Roth, and colleagues have delivered a pioneering tool that transcends traditional limitations of multiomics data utilization in clinical oncology. The Knowledge Connector harnesses the confluence of cutting-edge computational strategies and clinical expertise to illuminate the path toward truly personalized cancer therapy. Its scalable design, interpretability, and dynamic integration with real-world evidence collectively position it to redefine precision oncology as we know it. As this system gains traction, it heralds a new epoch wherein the complex molecular tapestry of cancer is unraveled with unprecedented clarity, offering renewed hope for patients worldwide.

The advent of the Knowledge Connector invites the oncology community to reconsider established workflows and embrace the power of integrative data analytics. With its capacity to generate mechanistic, personalized insights, this decision support system stands poised to become an indispensable ally in the fight against cancer. Already sparking excitement among clinicians and researchers, the platform epitomizes the promise of multiomics to transform patient outcomes and accelerate discovery.

Ultimately, the Knowledge Connector exemplifies how interdisciplinary collaboration and technological innovation can overcome entrenched challenges in precision medicine. By transforming voluminous, complex molecular data into clinically actionable intelligence, it bridges the gap between research and practice. As it enters broader clinical use, this system will likely inspire a new wave of data-driven strategies aimed at optimizing therapy selection and monitoring response, thereby elevating the standard of cancer care globally.

Subject of Research: Multiomics integration and decision support systems in precision oncology

Article Title: The Knowledge Connector decision support system for multiomics-based precision oncology

Article References:
Hübschmann, D., Kreutzfeldt, S., Roth, B. et al. The Knowledge Connector decision support system for multiomics-based precision oncology. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68333-3

Image Credits: AI Generated

The genesis of CCII marked a pivotal moment in cancer research, integrating cutting-edge immunological science with clinical insights to translate laboratory discoveries into viable therapies. This multidisciplinary center has notably doubled its faculty in immune-oncology from a modest ten to a dynamic twenty, creating a fertile environment that nurtures collaboration and accelerates translational research. This academic vigor directly complements the clinical prowess of the UofL Health – Brown Cancer Center, whose extensive trial programs are integral to advancing novel immunotherapies.

The essence of the CCII’s mission is underscored by the seamless bridging of fundamental immunology with clinical application. Utilizing innovative technologies such as the CyTOF instrument and Hyperion Imaging Mass Cytometry housed within their Functional Immunomics Core, researchers are able to dissect the tumor microenvironment with high-dimensional precision. These platforms provide unprecedented insights into immune cell phenotypes and their spatial distribution, fostering the development of therapies that precisely target cancer cells while sparing healthy tissue.

A particularly compelling aspect of the CCII’s work involves the strategic investigation into immune checkpoint inhibitor resistance, one of the foremost challenges in immunotherapy. By elucidating the cellular and molecular mechanisms that enable certain tumors to evade immune detection, researchers aim to design next-generation interventions that can overcome therapeutic resistance, thereby improving response rates in refractory cancers such as non-small cell lung cancer.

Clinical translation of CCII’s scientific discoveries finds a robust partner in the Brown Cancer Center, recognized nationally for its pioneering cellular therapies. Notably, the center has been a leader in tumor-infiltrating lymphocytes (TILs) therapy, a personalized treatment modality that expands a patient’s own T cells to target metastatic melanoma. This innovative therapy, after successive clinical trials and rigorous validation, attained FDA approval in 2024, signifying a watershed moment that cements the collaboration’s impact on patient survival and quality of life.

The clinical narrative is brought to life by patients like Julie Reynolds, whose journey through metastatic melanoma was transformed by the first commercial application of FDA-approved TILs therapy. Her case epitomizes the life-saving potential of translational research, where laboratory bench discoveries evolve into tangible clinical solutions, affording patients renewed hope and extended longevity.

Central to the CCII’s vision is the dedicated investment in nurturing the careers of emerging scientists who will drive the future of cancer immunotherapy. The NIH CoBRE funding framework supports junior investigators through comprehensive mentorship and access to advanced research infrastructures, facilitating their transition to independent researchers. The success of this strategy is evident, with all four initial CCII young investigators securing substantial federal funding, underscoring a vibrant pipeline of innovative research.

Noteworthy among the early career scientists is Kavitha Yaddanapudi, whose investigations into mechanisms of treatment resistance and immune profiling have directly enriched the clinical protocols at Brown Cancer Center. Her progression from mentee to mentor exemplifies the center’s ethos of building a collaborative, thriving scientific community committed to overcoming cancer.

Parallel support is extended to promising investigators like Joseph Chen, Sharmila Nair, and Jian Zheng, each leveraging CCII’s resources to develop nuanced understanding of tumor immunobiology. Their projects are instrumental in unveiling novel immune modulatory pathways and therapeutic targets, setting the stage for next-generation immunotherapies.

The Functional Immunomics Core serves as the technological backbone of the CCII, enabling comprehensive immune monitoring through high-parameter cytometry and imaging. This core facility not only enhances the quality and scope of CCII’s research but also empowers investigators across the university to pursue interdisciplinary cancer studies, catalyzing a multiplier effect in scientific discovery and innovation.

Looking forward, an exciting advancement is the planned integration of a tumor organoid fragment culture platform within CCII. This sophisticated ex vivo system authentically mimics the human tumor microenvironment, allowing precise evaluation of immunotherapeutic agents and facilitating personalized medicine approaches. By replicating the complex interactions between cancer cells and the immune milieu, tumor organoids represent a critical step towards customized treatment regimens with higher efficacy and reduced toxicity.

This expansive program at the University of Louisville epitomizes the aspirational vision of modern cancer research—melding rigorous basic science with compassionate clinical application to redefine patient outcomes. The sustained NIH funding will not only fuel scientific innovation but also fortify the infrastructure for training transformative cancer immunologists and clinicians, ensuring that advancements in cancer immunotherapy continue to evolve and reach patients locally, nationally, and worldwide.

Subject of Research: Cancer immunotherapy, immune-oncology research, tumor-infiltrating lymphocytes (TILs) therapy, immune checkpoint inhibitor resistance, translational cancer research
Article Title: University of Louisville Advances Cancer Immunotherapy with $11.5 Million NIH Grant to Propel Translational Research and Training
News Publication Date: Not specified
Web References:
– https://news.louisville.edu/news/uofl-receives-115-million-advance-cancer-immunotherapies
– https://uoflhealth.org/locations/brown-cancer-center/
– https://uoflhealth.org/news/brown-cancer-center-clinical-trial-leads-to-fda-approval-of-game-changing-cancer-treatment/
References: Not specified
Image Credits: University of Louisville
Keywords: Cancer immunotherapy, Immunology, Medical treatments, Cancer

The study, conducted by a multidisciplinary team at the Siteman Cancer Center affiliated with Barnes-Jewish Hospital and Washington University School of Medicine, involved monitoring patients’ smoking status over six months following their initial oncology clinic visit. Among the cohort, 13% identified as current smokers at baseline, and out of these individuals, 22.1% successfully quit within six months. Strikingly, patients who continued smoking exhibited a 97% higher risk of death within two years compared to their counterparts who quit, underscoring the profound impact of smoking cessation on cancer prognosis.

This investigation gains particular significance in the context of introducing the ELEVATE system—a pioneering electronic health record (EHR)-integrated tool developed under the National Cancer Institute’s (NCI) Cancer Moonshot program’s Cancer Center Cessation Initiative (C3I). ELEVATE streamlines the process of systematically assessing smoking status and deploying effective cessation interventions during oncology care encounters. The synchronization of this program-wide tool with routine cancer treatment exemplifies a transformative approach toward embedding tobacco cessation as a fundamental aspect of comprehensive cancer management.

Dr. Steven Tohmasi, MD, MPHS, the lead author, emphasizes that the magnitude of survival benefit observed rivals, and in some cases exceeds, that afforded by some chemotherapies. He advocates for positioning smoking cessation as the fourth pillar of cancer care, alongside surgery, radiation, and systemic therapies. Dr. Tohmasi stresses that incorporating cessation support directly into oncology treatment algorithms promises not only to prolong life but also to enhance patients’ quality of life, delivering truly holistic care.

Furthermore, senior co-author Dr. Li-Shiun Chen, MD, MPH, ScD, highlights that cessation benefits extend even to patients with late-stage cancer (stages III and IV), dismantling the misconception that it is “too late” or futile to quit smoking after a severe diagnosis. Dr. Chen’s insights support a paradigm shift wherein tobacco cessation is normalized as a standard therapeutic intervention, integrated ubiquitously across all stages of cancer care.

The study’s methodology blends rigorous observational design with pragmatic clinical implementation, encompassing a diverse population that reflects real-world oncology practice. Researchers captured longitudinal survival data, correlated with self-reported smoking cessation status, and adjusted for variables such as cancer type, stage, and treatment modalities. By deploying the ELEVATE system, oncologists received prompt alerts and streamlined workflows to assess readiness to quit and implement evidence-based interventions, including pharmacotherapy and behavioral counseling.

These findings resonate with existing literature establishing tobacco use as a potent carcinogen and a driver of treatment complications but extend this knowledge by quantifying the direct survival benefits linked to quitting during survivorship. Despite these benefits, the low cessation rate of approximately 20% within six months signals a critical need for enhanced engagement strategies. Barriers include nicotine addiction severity, psychosocial challenges, and insufficient integration of cessation support into oncology workflows.

The National Comprehensive Cancer Network (NCCN) plays a pivotal role by providing rigorously developed guidelines that offer clinicians structured protocols for tobacco assessment and intervention. The NCCN Guidelines for Smoking Cessation translate scientific evidence into actionable clinical pathways, ranging from assessing patient readiness and motivation to recommending FDA-approved cessation medications and delivering tailored counseling services.

Complementing provider-focused resources, the NCCN also publishes patient-centric materials designed to empower individuals with accessible, comprehensible information encouraging sustained quit attempts between clinic visits. These dual streams of resources aim to foster a cohesive cessation ecosystem within cancer care settings, facilitating a culture where quitting smoking is universally expected and supported.

Outside commentary from Dr. James M. Davis, MD, Associate Professor at Duke Cancer Institute and an NCCN Smoking Cessation Guidelines panel member, recognizes the study’s impressive demonstration of a two-fold reduction in all-cause mortality among quitters. While emphasizing the observational nature of the research precludes definitive causal inference, Dr. Davis acknowledges that the magnitude of this association aligns with extensive prior evidence implicating smoking as deleterious to cancer outcomes.

This pivotal research not only confirms that smoking cessation can significantly lower mortality risk but also underscores an urgent imperative to embed tobacco treatment into routine oncology protocols. As tobacco use remains a modifiable risk factor, its continuation undermines the efficacy of advanced cancer therapeutics and compromises patient survival.

In light of these findings, the cancer care community is called to action to leverage electronic health technologies like ELEVATE and adhere to NCCN’s evidence-based guidelines to systematically address tobacco dependence. Initiating cessation interventions promptly at diagnosis and sustaining support throughout the treatment continuum could redefine survivorship trajectories and improve long-term outcomes for millions of patients worldwide.

To delve deeper into this influential study entitled “Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute–Designated Cancer Center,” readers are encouraged to access the full text via JNCCN at JNCCN.org.

Subject of Research: People
Article Title: Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute–Designated Cancer Center
News Publication Date: 9-Oct-2025
Web References:

• Journal of the National Comprehensive Cancer Network
• NCCN Guidelines for Smoking Cessation
• NCCN Patient Guidelines for Quitting Smoking
  References:
• Tohmasi et al., “Smoking Cessation and Mortality Risk in Cancer Survivorship,” JNCCN, 2025; DOI: 10.6004/jnccn.2025.7059
  Image Credits: NCCN
  Keywords: Cancer, Health and medicine, Cancer research, Cancer treatments, Oncology, Behavior modification, Behavioral addiction